Low-dose rapamycin to protect elderly from COVID-19

Longevity researcher proposes clinical trials for low-dose rapamycin (and other geroprotectors) to protect the elderly from COVID-19.

The UK’s Biogerontology Research Foundation today announced the publication of a paper titled “Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections” in the leading journal Aging; timely in view of global devastation from COVID-19.

The author of the study, Alex Zhavoronkov, PhD, the chief scientist of the Biogerontology Research Foundation and the CEO of an artificial intelligence company Insilico Medicine proposed calling SARS-CoV-2 (which causes COVID-19) and other infections that are more infectious and harmful to the elderly as ‘gerophilic’ and ‘gerolavic’ infections: 2 new phrases to get our heads around.

Longevity.Technology: Vaccines and therapeutic solutions for COVID-19 are still far from the clinic and will not provide complete protection, and likely to be less effective in the elderly [1]. Could this proposed study and supporting paper set a pathway for protecting the elderly in the case of an extended epidemic or new coronavirus?

Zhavoronkov also proposed a strategy for repurposing known geroprotectors such as rapamycin, nicotinamide riboside, nicotinamide mononucleotide, metformin, and other drugs with the known safety profile for prevention of SARS-CoV-2 infection. The scientist analyzed the prior clinical studies of everolimus (RAD001) in healthy elderly, and previous evidence showing paradoxical immunopotentiation effects of rapamycin and proposed additional clinical trials for these molecules in the healthy elderly population.

COVID-19 aging
Source: The Biogerontology Research Foundation

Zhavoronkov also proposed the use of inexpensive and minimally-invasive deep aging clocks to track the efficacy of these preventative geroprotective interventions and to stratify the patients by predicted severity of COVID-19.

Longevity Technology Deep Aging Clock
Prospective Applications of Deep Aging Clocks in the Pharmaceutical and Biotechnology Industries. Source: Trends in Pharmacological Sciences

In 2019 Zhavoronkov and fellow Insilco Medicine colleague, Polina Mamoshina, published a paper [2] which addressed deep aging clocks which combine various machine learning models based on large data sets derived from: blood biochemistry and cell count; photographic images (such as the corners of the eye); gene expression data from muscle tissue; and wearable device data.

“We are pursuing several strategies for drug discovery and repurposing using the latest advances in artificial intelligence integrated into our battle-tested discovery platform. However, it is clear that COVID-19 is a gerophilic and gerolavic disease. It is more severe and lethal in the elderly. Aging research yields insights that may not only help with COVID-19 but may help prevent many other diseases and increase productive longevity and re-ignite the economy”, said Alex Zhavoronkov, PhD.

Previous studies by the BGRF scientists [3] and books including “The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy” show that extending productive longevity in the developed countries will lead to unprecedented economic growth.

“Most of the companies and institutions are racing to create vaccines or drugs that target COVID directly. But these interventions will not offer complete protection. We see that children and very young people do not have severe symptoms. Geroprotectors may help improve the odds for the elderly. And once the epidemic subsides, we will need to find new ways to boost the economy and there are established models showing that the best way to grow the economy is by increasing healthy productive longevity”, said Dmitry Kaminskiy, managing trustee of the Biogerontology Research Foundation.

“This is the first review highlighting geroprotective strategies that may decrease the disease burden of gerolavic infections such as COVID-19. It presents a case for further research and clinical studies to validate markers of biological age in the context of viral infections. Ageing Research at King’s (ARK) is partnering with BGRF and Insilico Medicine to identify mechanisms by which geroprotectors enhance resilience against infections and reduce the severity of symptoms. The proposed research will acutely help physicians treat COVID-19, protect the elderly and benefit long term global health and longevity.” said Dr Richard Siow, Director of ARK and former Vice-Dean (International), Faculty of Life Sciences & Medicine, King’s College London.

[1] https://www.bbc.co.uk/news/health-51665497

[2] https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(19)30114-2

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863879/

Images courtesy of the Biogerontology Research Foundation
Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...

G3 and Juvenescence partner on deep learning venture

G3 Therapeutics and Juvenescence announce the formation of Juvenomics to apply deep molecular profiling and deep learning to tackle aging. Juvenomics, a joint venture between...

Building an artificial immune system

DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...

Neurotech is the new blue ocean

Alon Braun, Co-Founder, Neurotech Analytics.